Kestra Medical Technologies LTD (KMTS) is trading up at $28.32 (+3.70%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2024Apr 2024 | FY2025Apr 2025 | FY2026Apr 2026 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $27.8M | $59.8M | $95.1M |
| Growth (year over year) | — | +115.1% | +59.0% |
| Gross profit | $362.0K | $24.2M | $48.9M |
| Gross margin | 1.3% | 40.5% | 51.4% |
| Operating income | −$85.1M | −$106.4M | −$134.7M |
| Operating margin | −305.8% | −177.8% | −141.6% |
| Net income | −$94.1M | −$113.8M | −$131.6M |
| Net margin | −338.4% | −190.3% | −138.4% |
| EPS (diluted) | −$5.07 | −$5.13 | −$2.43 |
| Balance sheet | |||
| Cash and equivalents | $8.25M | $237.6M | $99.7M |
| Total assets | $45.9M | $295.7M | $358.5M |
| Total liabilities | $78.2M | $90.3M | $98.8M |
| Long-term debt | $42.5M | $41.1M | $42.6M |
| Shareholders' equity | −$209.4M | $205.4M | $259.7M |
| Cash flow | |||
| Operating cash flow | −$72.2M | −$77.6M | −$81.7M |
| Capital expenditure | $12.2M | $22.9M | $34.9M |
| Free cash flow | −$84.5M | −$100.5M | −$116.6M |
| Q2 FY25Oct 2024 | Q3 FY25Jan 2025 | Q4 FY25†Apr 2025 | Q1 FY26Jul 2025 | Q2 FY26Oct 2025 | Q3 FY26Jan 2026 | Q4 FY26†Apr 2026 | Q1 FY27Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.7M | $15.1M | $17.2M | $19.4M | $22.6M | $24.6M | $28.6M | $31.0M |
| Growth (year over year) | — | — | — | +51.5% | +53.4% | +62.7% | +66.2% | +59.9% |
| Gross profit | $5.83M | $6.55M | $7.63M | $8.85M | $11.4M | $12.9M | $15.7M | $17.5M |
| Gross margin | 39.6% | 43.4% | 44.3% | 45.7% | 50.6% | 52.6% | 54.8% | 56.5% |
| Operating income | −$19.1M | −$20.6M | −$48.2M | −$28.9M | −$31.8M | −$34.8M | −$39.3M | −$37.7M |
| Operating margin | −130.1% | −136.5% | −279.8% | −149.1% | −140.7% | −141.6% | −137.4% | −121.6% |
| Net income | −$20.4M | −$21.5M | −$52.1M | −$25.8M | −$32.8M | −$34.2M | −$38.8M | −$44.1M |
| Net margin | −138.5% | −142.5% | −302.1% | −133.3% | −145.3% | −139.2% | −135.6% | −142.3% |
| EPS (diluted) | −$1.19 | −$1.25 | −$1.57 | −$0.50 | −$0.64 | −$0.61 | −$0.68 | −$0.75 |
| Balance sheet | ||||||||
| Cash and equivalents | $76.9M | $54.4M | $237.6M | $201.2M | $175.4M | $291.3M | $99.7M | $68.6M |
| Total assets | — | — | $295.7M | $266.3M | $246.7M | $379.3M | $358.5M | $347.4M |
| Total liabilities | — | — | $90.3M | $82.1M | $82.6M | $91.4M | $98.8M | $125.0M |
| Long-term debt | — | — | $41.1M | $41.5M | $41.9M | $42.3M | $42.6M | $72.5M |
| Shareholders' equity | −$236.5M | −$257.9M | $205.4M | $184.2M | $164.1M | $288.0M | $259.7M | $222.4M |
| Cash flow | ||||||||
| Operating cash flow | −$18.1M | −$18.0M | −$24.1M | −$26.3M | −$18.3M | −$18.4M | −$18.7M | −$32.3M |
| Capital expenditure | $4.45M | $4.06M | $7.39M | $8.17M | $7.26M | $9.80M | $9.66M | $8.34M |
| Free cash flow | −$22.5M | −$22.1M | −$31.4M | −$34.4M | −$25.6M | −$28.2M | −$28.4M | −$40.6M |
From Kestra Medical Technologies LTD's 10-K and 10-Q filings with the SEC; its fiscal year ends in April. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Kestra Medical Technologies LTD in our feed yet.